title: [Prevalence of anti hepatitis C antibodies in patients with chronic renal failure receiving conservative therapy].
abstract: The prevalence of hepatitis C varies according to geographical areas and risk groups. Patients with terminal chronic renal failure (TCRF) under dialysis are an important risk group. In Peru, hepatitis C virus (HCV) infection rates in patients under hemo-dialysis reach 90%, and are associated with transfusions and time under dialysis as risk factors. Little is known about the prevalence of HCV in patients with TCRF receiving non dialysis therapy. The purpose of this study is to know the prevalence of HCV infection in these patients and to determine the risk factors.
  
  
  METHODS
  Prospective study, anti-hepatitis C (anti HCV) antibodies were assessed in patients with TCRF in non-dialysis conservative therapy at the Department of Nephrology of the Arzobispo Loayza Hospital.
  
  
  RESULTS
  Ninety nine (99) patients were studied, 54.1% male and 45.8% female, with an average age of 56.6 + 17.9 years, with an average time of CRF diagnosis of 9.28 + 14.35 months. The most frequent cause of CRF was the unknown cause, followed by diabetes. A rate of anti HCV of 1.01% (1/99) was found.
  
  
  CONCLUSIONS
  A low prevalence of antiHCV was found in the population studied. It was similar to the rates found in populations without CTRF.
authors.affiliation: Servicio de Gastroenterologia, Hospital Nacional Cayetano Heredia, Universidad Peruana Cayetano Heredia, Lima, Perú.
authors.forename: Raúl
authors.initials: R
authors.lastname: de Los Ríos
authors.forename: Alejandro
authors.initials: A
authors.lastname: Bussalleu
authors.forename: Abdías
authors.initials: A
authors.lastname: Hurtado
authors.forename: José
authors.initials: J
authors.lastname: Valdivia
authors.forename: Jorge
authors.initials: J
authors.lastname: Huerta Mercado
authors.forename: Carlos
authors.initials: C
authors.lastname: Battilana
authors.forename: Marco
authors.initials: M
authors.lastname: Pala
authors.forename: José Luís
authors.initials: JL
authors.lastname: Pinto
authors.forename: Alejandro
authors.initials: A
authors.lastname: Piscoya
authors.forename: Hugo
authors.initials: H
authors.lastname: Cedrón
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D010568:Peru / Q000453:epidemiology; D015995:Prevalence; D011446:Prospective Studies; D006435:Renal Dialysis / Q000706:statistics & numerical data
chemical_list: D018937:Hepatitis C Antibodies